<p>因塞特医疗（Incyte，INCY）最近公布了令人印象深刻的第三季度业绩，强劲的收入增长超出了预期。财报发布引发了投资者的积极反应，随着公司肿瘤学管线的扩展和即将到来的里程碑，市场的兴奋情绪不断上升。</p>
<p>查看我们对因塞特医疗的最新分析。</p>
<p>因塞特医疗的势头显然加速，过去 30 天的股价回报率为 18.15%，年初至今的总回报率为 49.79%。这突显了强劲的业绩和有前景的肿瘤学发展如何改变了市场情绪，尽管近期有一些内部人士抛售和空头头寸上升。长期持有者在过去一年中也获得了丰厚的回报，总股东回报率为 37.27%。</p>
<p>如果因塞特医疗的管线进展让你考虑更大的机会，现在可能是发现完整列表的合适时机，免费获取。</p>
<p>随着股票今年大幅上涨，分析师对其未来前景意见不一，投资者现在面临一个重要问题：因塞特医疗的强劲增长是否已经反映在其股价中，还是仍然存在吸引人的买入机会？</p>
<h2>最受欢迎的观点：高估 11%</h2>
<p>与因塞特医疗最后的收盘价 104.15 美元相比，最受欢迎的观点估计公允价值为 93.82 美元，这表明分析师目前认为该股交易价格高于他们认为基本面所能支持的水平。这为深入分析影响该观点的驱动因素和不确定性奠定了基础。</p>
<blockquote>
<p><em>公司的资本配置策略更加严谨，优先考虑内部晚期管线资产、控制运营费用和有针对性的业务发展，表明运营杠杆和净利润率的提升，正如指导意见所示，运营费用的增长速度将低于收入的增长。加强和多样化的产品组合势头（包括 Jakafi、Opzelura、Niktimvo、Monjuvi 和 Zynyz 均实现了强劲增长）以及活跃的业务发展管线增强了抵御生物仿制药/仿制药威胁的韧性，并可能降低近期或中期收入的风险，表明当前估值并未完全反映未来收益的稳定性或新产品成功带来的潜在上行空间。</em></p>
</blockquote>
<p>阅读完整观点。</p>
<p>想知道是什么真正推动因塞特医疗的估值争论吗？现金流故事、利润率目标和乐观假设将这些数字串联在一起——一个大胆的预测将它们全部联系在一起。哪些高风险的增长预测在这个计算中起到了关键作用？这个公允价值的惊人基础可能会挑战你的预期。</p>
<p><strong>结果：公允价值为 93.82 美元（高估）</strong></p>
<p>完整阅读观点，了解预测背后的原因。</p>
<p>然而，持续依赖 Jakafi 以及管线可能出现的挫折可能会迅速挑战当前估值中反映的乐观前景。</p>
<p>了解因塞特医疗观点的关键风险。</p>
<h2>另一种观点：我们的 DCF 模型显示低估</h2>
<p>虽然许多分析师基于传统市场比率认为因塞特医疗被高估，但我们的 SWS DCF 模型则讲述了不同的故事。根据我们的估计，该股的交易价格约低于其公允价值的 36%。这表明市场当前可能错过了显著的上行空间。关注长期现金流是否意味着真正的机会，还是市场有理由保持谨慎？</p>
<p>深入了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dead717-1ae6-45ad-8199-2f5708ff37ae/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dead717-1ae6-45ad-8199-2f5708ff37ae/chart/dcf"/></p>
<p>截至 2025 年 11 月的 INCY 折现现金流</p>
<h2>构建你自己的因塞特医疗观点</h2>
<p>如果你想深入探讨或更愿意形成自己的结论，你可以在几分钟内构建一个自定义观点。按照你的方式进行。</p>
<p>进行因塞特医疗研究的一个很好的起点是我们的分析，强调了 3 个关键回报和 1 个可能影响你投资决策的重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>通过超越因塞特医疗来提升你的投资组合。市场上充满了被忽视的机会，等待被发现。现在就开始，不要让最佳想法从你身边溜走。</p>
<ul>
<li>通过扫描这些 877 只被低估的股票，发现下一波回报，这些股票基于现金流，市场仍在忽视，但具有强劲的现金流潜力。</li>
<li>通过探索这些 16 只股息收益率超过 3% 的股息股票，锁定可靠的收入来源，提供高于平均水平的收益和稳定的表现，以增强长期信心。</li>
<li>乘着数字金融的浪潮，发现这些 82 只处于区块链创新前沿的加密货币和区块链股票的增长前景。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在任何提到的股票中没有持仓。</em></p>

因塞特医疗

<p>因塞特医疗 (Incyte) 报告了强劲的第三季度财报，提升了投资者的乐观情绪，30 天的股价回报率为 18.15%，年初至今的总回报率为 49.79%。尽管内部人士抛售和高空头头寸，长期持有者在过去一年中获得了 37.27% 的回报。分析师对其估值意见不一，有些人认为以 104.15 美元的价格被高估，相较于 93.82 美元的公允价值，而另一些人则使用现金流折现模型认为其被低估。公司的肿瘤学管线和严谨的资本策略是其估值争论的关键因素</p>

<p>Incyte (INCY) recently reported impressive third quarter results, with strong revenue growth that surpassed expectations. The earnings release drew a positive reaction from investors as excitement builds around the company's expanding oncology pipeline and upcoming milestones.</p>
<div class="lb-trans"><p>因塞特医疗（Incyte，INCY）最近公布了令人印象深刻的第三季度业绩，强劲的收入增长超出了预期。财报发布引发了投资者的积极反应，随着公司肿瘤学管线的扩展和即将到来的里程碑，市场的兴奋情绪不断上升。</p>
</div><p>See our latest analysis for Incyte.</p>
<div class="lb-trans"><p>查看我们对因塞特医疗的最新分析。</p>
</div><p>Momentum has clearly accelerated for Incyte, with a 30-day share price return of 18.15% and a total return of 49.79% year-to-date. This underscores how strong earnings and promising oncology developments have shifted sentiment despite some recent insider selling and elevated short interest. Long-term holders have also seen solid rewards, with a 37.27% total shareholder return over the past year.</p>
<div class="lb-trans"><p>因塞特医疗的势头显然加速，过去 30 天的股价回报率为 18.15%，年初至今的总回报率为 49.79%。这突显了强劲的业绩和有前景的肿瘤学发展如何改变了市场情绪，尽管近期有一些内部人士抛售和空头头寸上升。长期持有者在过去一年中也获得了丰厚的回报，总股东回报率为 37.27%。</p>
</div><p>If Incyte’s pipeline progress has you thinking bigger, this could be the right moment to discover See the full list for free.</p>
<div class="lb-trans"><p>如果因塞特医疗的管线进展让你考虑更大的机会，现在可能是发现完整列表的合适时机，免费获取。</p>
</div><p>With the stock rallying sharply this year and analysts divided on its future prospects, investors now face an important question: Is Incyte’s strong growth already reflected in its share price, or is there still an attractive buying opportunity ahead?</p>
<div class="lb-trans"><p>随着股票今年大幅上涨，分析师对其未来前景意见不一，投资者现在面临一个重要问题：因塞特医疗的强劲增长是否已经反映在其股价中，还是仍然存在吸引人的买入机会？</p>
</div><h2>Most Popular Narrative: 11% Overvalued</h2>
<div class="lb-trans"><h2>最受欢迎的观点：高估 11%</h2>
</div><p>Compared to Incyte’s last closing price of $104.15, the most popular narrative estimates a fair value at $93.82, indicating analysts currently see the shares as trading above where they believe the fundamentals justify. This sets the stage for a close look at the drivers and uncertainties shaping that view.</p>
<div class="lb-trans"><p>与因塞特医疗最后的收盘价 104.15 美元相比，最受欢迎的观点估计公允价值为 93.82 美元，这表明分析师目前认为该股交易价格高于他们认为基本面所能支持的水平。这为深入分析影响该观点的驱动因素和不确定性奠定了基础。</p>
</div><blockquote>
<p><em>The company’s more disciplined capital allocation strategy, prioritizing internal late-stage pipeline assets, operating expense control, and targeted business development, suggests increasing operating leverage and net margin expansion, as evidenced by guidance for operating expenses to grow more slowly than revenues. Strengthened and diversified product portfolio momentum (with Jakafi, Opzelura, Niktimvo, Monjuvi, and Zynyz all delivering robust growth) alongside an active business development pipeline increases resilience against biosimilar/generic threats and potentially derisks near- or mid-term revenue, suggesting the current valuation does not fully reflect future earnings stability or potential upside from new product successes.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>公司的资本配置策略更加严谨，优先考虑内部晚期管线资产、控制运营费用和有针对性的业务发展，表明运营杠杆和净利润率的提升，正如指导意见所示，运营费用的增长速度将低于收入的增长。加强和多样化的产品组合势头（包括 Jakafi、Opzelura、Niktimvo、Monjuvi 和 Zynyz 均实现了强劲增长）以及活跃的业务发展管线增强了抵御生物仿制药/仿制药威胁的韧性，并可能降低近期或中期收入的风险，表明当前估值并未完全反映未来收益的稳定性或新产品成功带来的潜在上行空间。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整观点。</p>
</div><p>Want to know what’s really fueling Incyte’s valuation debate? The cash flow story, margin ambitions, and bullish assumptions that pull the numbers together—one bold projection links them all. Which high-stakes growth forecasts tip the scales in this calculation? The surprising foundation of this fair value might test your expectations.</p>
<div class="lb-trans"><p>想知道是什么真正推动因塞特医疗的估值争论吗？现金流故事、利润率目标和乐观假设将这些数字串联在一起——一个大胆的预测将它们全部联系在一起。哪些高风险的增长预测在这个计算中起到了关键作用？这个公允价值的惊人基础可能会挑战你的预期。</p>
</div><p><strong>Result: Fair Value of $93.82 (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 93.82 美元（高估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读观点，了解预测背后的原因。</p>
</div><p>However, persistent reliance on Jakafi and the potential for pipeline setbacks could quickly challenge the upbeat outlook that is reflected in today's valuation.</p>
<div class="lb-trans"><p>然而，持续依赖 Jakafi 以及管线可能出现的挫折可能会迅速挑战当前估值中反映的乐观前景。</p>
</div><p>Find out about the key risks to this Incyte narrative.</p>
<div class="lb-trans"><p>了解因塞特医疗观点的关键风险。</p>
</div><h2>Another View: Our DCF Model Signals Undervaluation</h2>
<div class="lb-trans"><h2>另一种观点：我们的 DCF 模型显示低估</h2>
</div><p>While many analysts see Incyte as overvalued based on traditional market ratios, our SWS DCF model tells a different story. According to our estimate, the shares are trading about 36% below their fair value. This suggests there could be significant upside that the market is currently missing. Could a focus on long-term cash flows signal a real opportunity, or is the market cautious for a good reason?</p>
<div class="lb-trans"><p>虽然许多分析师基于传统市场比率认为因塞特医疗被高估，但我们的 SWS DCF 模型则讲述了不同的故事。根据我们的估计，该股的交易价格约低于其公允价值的 36%。这表明市场当前可能错过了显著的上行空间。关注长期现金流是否意味着真正的机会，还是市场有理由保持谨慎？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>深入了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dead717-1ae6-45ad-8199-2f5708ff37ae/chart/dcf" alt="" original-src="https://images.simplywall.st/company/4dead717-1ae6-45ad-8199-2f5708ff37ae/chart/dcf"/></p>
<p>INCY Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>截至 2025 年 11 月的 INCY 折现现金流</p>
</div><h2>Build Your Own Incyte Narrative</h2>
<div class="lb-trans"><h2>构建你自己的因塞特医疗观点</h2>
</div><p>If you want a deeper dive or would rather form your own conclusions, you can build a custom narrative in just a few minutes. Do it your way</p>
<div class="lb-trans"><p>如果你想深入探讨或更愿意形成自己的结论，你可以在几分钟内构建一个自定义观点。按照你的方式进行。</p>
</div><p>A great starting point for your Incyte research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</p>
<div class="lb-trans"><p>进行因塞特医疗研究的一个很好的起点是我们的分析，强调了 3 个关键回报和 1 个可能影响你投资决策的重要警示信号。</p>
</div><h2>Looking for More Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Level up your portfolio by searching beyond Incyte. The market is brimming with overlooked opportunities just waiting to be found. Start now and don’t let the best ideas pass you by.</p>
<div class="lb-trans"><p>通过超越因塞特医疗来提升你的投资组合。市场上充满了被忽视的机会，等待被发现。现在就开始，不要让最佳想法从你身边溜走。</p>
</div><ul>
<li>Spot the next wave of returns by scanning for these 877 undervalued stocks based on cash flows that the market is still overlooking but have strong cash flow potential.</li>
<li>Target reliable income streams by exploring these 16 dividend stocks with yields &gt; 3% offering above-average yields and steady performance for long-term confidence.</li>
<li>Ride the digital finance surge and uncover growth frontiers with these 82 cryptocurrency and blockchain stocks at the forefront of blockchain innovation.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描这些 877 只被低估的股票，发现下一波回报，这些股票基于现金流，市场仍在忽视，但具有强劲的现金流潜力。</li>
<li>通过探索这些 16 只股息收益率超过 3% 的股息股票，锁定可靠的收入来源，提供高于平均水平的收益和稳定的表现，以增强长期信心。</li>
<li>乘着数字金融的浪潮，发现这些 82 只处于区块链创新前沿的加密货币和区块链股票的增长前景。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在任何提到的股票中没有持仓。</em></p>
</div>

因塞特医疗（INCY）估值：在强劲的收益、肿瘤研发管线进展以及投资者乐观情绪的背景下评估股票